Orbis Investment Management Increases Stake in CRISPR Therapeutics AG to 6.3%

Orbis Investment Management Ltd, in conjunction with Allan Gray Australia Pty Ltd, has filed a Schedule 13G/A reporting a significant increase in their position in CRISPR Therapeutics AG (CRSP). As of the event date on March 31, 2026, the reporting persons collectively hold 6,106,011 shares of common stock, representing a 6.3% ownership stake in the company. Specifically, Orbis Investment Management Ltd holds 6,090,194 shares, while Allan Gray Australia Pty Ltd holds 15,817 shares. This filing marks a substantial increase from a previously reported 0.0% ownership, indicating a new major position for the group. The reporting persons are classified as non-U.S. institutions equivalent to investment advisers. The shares were acquired in the ordinary course of business and not for the purpose of influencing control over the issuer. Both entities have sole voting and dispositive power over their respective shares, though they disclaim beneficial ownership of shares held by each other and do not formally represent themselves as a group under Section 13(d)(3).